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Background: Inflammatory bowel diseases (IBD) are intestinal disorders characterized by inflammation in the
gastrointestinal tract. Interleukin-10 is one of the most important anti-inflammatory cytokines involved in the
intestinal immune system and because of its role in downregulating inflammatory cascades, its potential for IBD
therapy is under study. We previously presented the development of an invasive strain of Lactococcus lactis
(L. lactis) producing Fibronectin Binding Protein A (FnBPA) which was capable of delivering, directly to host cells,
a eukaryotic DNA expression vector coding for IL-10 of Mus musculus (pValac:il-10) and diminish inflammation
in a trinitrobenzene sulfonic acid (TNBS)-induced mouse model of intestinal inflammation. As a new therapeutic
strategy against IBD, the aim of this work was to evaluate the therapeutic effect of two L. lactis strains (the same
invasive strain evaluated previously and the wild-type strain) carrying the therapeutic pValac:il-10 plasmid in the
prevention of inflammation in a dextran sodium sulphate (DSS)-induced mouse model.
Results: Results obtained showed that not only delivery of the pValac:il-10 plasmid by the invasive strain L. lactis
MG1363 FnBPA+, but also by the wild-type strain L. lactis MG1363, was effective at diminishing intestinal inflammation
(lower inflammation scores and higher IL-10 levels in the intestinal tissues, accompanied by decrease of IL-6) in the
DSS-induced IBD mouse model.
Conclusions: Administration of both L. lactis strains carrying the pValac:il-10 plasmid was effective at diminishing
inflammation in this murine model of experimental colitis, showing their potential for therapeutic intervention of IBD.Background
Inflammatory bowel diseases (IBD), including ulcerative
colitis (UC) and Crohn’s disease (CD), are characterized
by spontaneous and chronic inflammation of the gastro-
intestinal tract (GIT). Despite much research in the last
years, the exact etiology and pathogenesis of these disorders
remain unclear; however, it is nowadays generally accepted
that IBD are caused by dysregulation of the mucosal
immune system in relation to the native intestinal* Correspondence: miyoshi@icb.ufmg.br
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Current treatments for IBD are restricted to the use of
anti-inflammatory drugs, immunosuppressants and antibi-
otics, which although showing moderate therapeutic effect,
present serious side effects and reveal that better, cheaper
and longer lasting drugs are necessary [2].
Interleukin-10 (IL-10) is one of the most important
anti-inflammatory cytokines involved in the intestinal
immune system [3] and because of its immunosuppres-
sive activity and its central role in downregulating in-
flammatory cascades [4] it presents itself as a good
therapeutic candidate against IBD [5]. Recombinant hu-
man IL-10 raised hope when first used in the 90s in CDtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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that were otherwise refractory to treatment [6]; however,
two large, multi-centered follow-up studies using
subcutaneous dosing were unable to confirm the re-
sults [7,8]. Moreover, systemic treatment with IL-10
showed to be quite limiting because of its short
half-life (1.1-2.6 h) and requirement of high protein
concentration (20 μg/kg), increasing the cost of pro-
duction, discomfort and secondary effects in the pa-
tients [9]. On the other hand, oral treatment with
IL-10 has also shown to be limited due to its ex-
treme sensitivity to the environment of the GIT and
therefore survival in it [10].
New approaches to yield more specific delivery of IL-
10 to the intestinal mucosa and prevent the drawbacks
associated to systemic and oral administration led to
the development of IL-10-producing Lactococcus lactis
(L. lactis) strains [11]. In 2003, a biological contain-
ment system for human IL-10-producing L. lactis [12]
showed to be safe and improved the disease when
tested in CD patients in phase I clinical trials [13];
however, clinical results did not reveal a statistically
significant difference in mucosal healing between pa-
tients receiving the recombinant strains and placebo.
Since this strain produces IL-10 and releases it in the
GIT, its clinical use for IBD is still hindered by IL-10’s
sensitivity and poor survival in these hostile conditions.
In this regard, a new eukaryotic DNA expression vector
for delivery using lactococci, called pValac, which allows
cloning of an ORF (Open Reading Frame) of interest, ex-
pression of the molecule by host cells, replication both
in E. coli and in L. lactis and selection of bacteria, was
firstly constructed in 2009 [14]. Its potential to deliver
DNA and trigger DNA expression by epithelial cells has
already been demonstrated in vitro [15] and in vivo [16].
This strategy does not only fulfil the aforementioned ad-
vantages, but also combines the advantages of mucosal
immunity, safety of using non-pathogenic bacteria, tech-
nique simplicity and low cost of DNA therapy. Moreover,
ingested L. lactis strains pose no risk to the individuals as
these bacteria are quickly degraded and only around 20-
30% reach the sites of inflammation, their transit through
the gastrointestinal tract takes between 2 to 3 days and they
are incapable of multiplying in the body or become part of
the normal gut flora.
Our research group recently evaluated a recombinant
invasive L. lactis strain expressing the Staphylococcus
aureus Fibronectin Binding Protein A (FnBPA), harbour-
ing the eukaryotic DNA expression vector pValac coding
for the anti-inflammatory cytokine IL-10 of Mus muscu-
lus (L. lactis MG1363 FnBPA + pValac:il-10), for in situ
expression of IL-10 and therefore higher, more effi-
cient and direct production of this cytokine at the sites
of inflammation. This strategy showed to be efficient atdiminishing inflammation in a TNBS-induced inflam-
matory mouse model [17].
The aim of the present work was to evaluate and com-
pare the therapeutic capacity of two L. lactis strains, the
invasive L. lactis MG1363 FnBPA + strain and the wt L.
lactis MG1363, both carrying the pValac:il-10 plasmid,
for the prevention of experimental IBD in a DSS-induced
mouse model.
Methods
Bacterial strains, growth conditions and plasmid
The bacterial strains used in this work are listed in Table 1.
E. coli TG1 was aerobically grown in Luria-Bertani (LB)
medium at 37°C with vigorous shaking whereas all L. lactis
[18] strains were grown in M17 medium (Difco, Sparks,
MD, USA) supplemented with 0.5% glucose (GM17) at
30°C without shaking. Recombinant E. coli were selected by
addition of 10 μg/mL chloramphenicol (Cm) while re-
combinant L. lactis were selected by addition of 10 μg/
mL Cm and/or 5 μg/mL of erythromycin (Ery). For
animal trials, L. lactis cultures grown until an OD600 of
1.0-1.2 were previously stocked in glycerol 80% (1:4)
and on day of use they were centrifuged in order to
eliminate any remaining traces of the antibiotic and
medium and resuspended in 100 μL of saline solution
(0.15 M NaCl) for animal feedings.
As previously shown by del Carmen and co-workers,
the pValac:il-10 plasmid harbours an eukaryotic region
containing the CytoMegaloVirus promoter (pCMV), the
IL-10 ORF of Mus musculus and the polyadenylation
signal of bovine growth hormone (BGH polyA), required
for gene expression by eukaryotic host cells, as well as a
prokaryotic region containing the RepA/RepC replica-
tion origins for both E. coli and L. lactis, respectively,
and a Cm resistance gene for bacterial selection [14].
DNA manipulations
General DNA manipulation techniques were carried out
according to standard procedures. Unless otherwise indi-
cated, DNA restriction and modification enzymes were
used as recommended by the suppliers. DNA fragments
were isolated from agarose gels using the Illustra GFX
PCR DNA and Gel Band Purification Kit (GE Healthcare
Life Sciences, Chalfont St. Giles, UK). PCR amplifications
were performed using AccuPrimePfx DNA Polymerase
(Invitrogen, Carlsbad, CA, USA) and/or GoTaq DNA Poly-
merase (Invitrogen, Carlsbad, CA, USA) in a DNA thermo-
cycler (MJ Research, Inc., Minnesota, USA). Plasmid DNA
from E. coli and L. lactis was isolated as previously de-
scribed [19] with the following modifications: for plasmid
DNA extraction from L. lactis, the first step included
addition of TES (25% sucrose, 1 mM EDTA, 50 mMTris-
HCl, pH 8) containing lysozyme (10 mg/mL) for 30 min at
37°C to prepare protoplasts. Electroporation of E. coli and
Table 1 Bacterial strains used in this work
Bacterial Strain Characteristics Reference
Escherichia coli
(E.coli) TG1
[supE, hsd, Δ5, thi,
Δlac-proAB), F’(traD36
proAB-lacZΔM15)]
Invitrogen (São Paulo,
Brazil)
Escherichia coli
(E.coli) TG1
(pValac:il-10)
(pCMV/CmR/RepA/
RepC/IL-10)
[17]
Lactococcus lactis
(L. lactis) MG1363
L. lactis subsp. cremorisb Laboratory of Cellular
and Molecular Genetics
(LGCM), Federal
University of Minas
Gerais (UFMG), Brazil
Lactococcus lactis
(L. lactis) MG1363
pValac:il-10
L. lactis MG1363 strain
carrying the pValac:il-10
plasmid
This work
Lactococcus lactis
(L. lactis) MG1363
FnBPA
L. lactis MG1363 strain
expressing FnBPA of
S. aureus
[19]
Lactococcus lactis
(L. lactis) MG1363
FnBPA pValac:il-10
L. lactis MG1363 strain
expressing FnBPA of
S. aureus carrying the
pValac:il-10 plasmid
[17]
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transformants were plated on LB agar plates containing the
required antibiotic for 24 h at 37°C, whereas L. lactis trans-
formants were plated on GM17 agar plates containing the
required antibiotic and were counted after 2-days incuba-
tion at 30°C.
Induction of intestinal inflammation and feeding
procedure in mice
Conventional female C57BL/6 mice [21] weighing approxi-
mately 18 g, obtained from the inbred closed colony
(CEBIO) maintained at the Federal University of Minas
Gerais (UFMG – Belo Horizonte, Brazil), were used to
evaluate the therapeutic effect of L. lactis MG1363 pValac:
il-10 and L. lactis MG1363 FnBPA + pValac:il-10 in the
prevention of intestinal inflammation in a DSS-induced
mouse model. Procedures and manipulation of animals
followed the rules of the ethics and research committees of
the Biological Institute of the UFMG and all animal proto-
cols were approved by the Ethics Committee on Animal
Experiments (CETEA). All animals were maintained in
collective cages (6 animals/cage) in an environmentally
controlled room with a 12-hour light/dark cycle and unlim-
ited free access to water (or DSS solution) and food. After
acclimatization for 17 days, colonic inflammation was in-
duced by the addition of 1.5% (w/v) DSS (MW 40,000-
50,000; USB Affymetrix, Santa Clara, CA, USA) in drinking
water for 7 consecutive days. Liquid consumption was
monitored to ensure that all mouse groups consumed
similar volumes (4 ± 2 mL) of the DSS solution daily. For
experimental procedure, mice were divided in 6 experimen-
tal groups: i) control group which received 100 μl NaClintragastrically while no DSS was added to the drinking
water; ii) DSS group which received 100 μl NaCl intragas-
trically while DSS was added to the drinking water and
iii) L. lactis MG1363 group (wt group), iv) L. lactis
MG1363 pValac:IL-10 group, v) L. lactis MG1363
FnBPA+ group and vi) L. lactis MG1363 FnBPA+ pValac:
il-10 group, which all received intragastrically 100 μl of the
corresponding bacterial strain as suspension, at a dose of
2×109 CFU/100 μl, in NaCl. The intragastric administration
of NaCl or the bacterial suspensions was once daily since
the day before the beginning of DSS administration until
sacrifice. At day 9, mice were sacrificed by cervical disloca-
tion for organ collection.
Macroscopic and microscopic (histological) assessment of
intestinal inflammation
On the day of sacrifice (day 9), colons were removed, ex-
cised and visually inspected for macroscopic evaluation
to assess colonic inflammation [disease activity index
(DAI)], using a scoring system in which the following
features were graded: body weight loss (0, no loss; 1, 1-
5% loss; 2, 5-10% loss; 3, 11-15% loss and 4, >15% loss),
diarrhoea (0, absent; 2, moderate; 4, severe) and rectal
bleeding (0, absent; 2, moderate; 4, severe). The macro-
scopic damage score was calculated from the score of all
clinical signs with a maximum score of 12. For histo-
logical inflammation scoring [histological activity index
(HAI)], samples of the colon were fixed in 10% formalin
in phosphate-buffered saline (PBS), embedded in paraf-
fin, cut into 3–5-μm sections and stained with haema-
toxylin–eosin (H&E-staining) for microscopic analysis.
These sections were blindly scored based on a semi
quantitative scoring system previously described [22] in
which the following features were graded: extent of
destruction of the mucosa’s architecture (0, normal; 1, 2
and 3, light, moderate and extensive damage, respectively),
presence and degree of cellular infiltration (0, normal; 1, 2
and 3, light, moderate and transmural infiltration, respect-
ively), extent of muscle thickening (0, normal; 1, 2 and 3,
light, moderate and extensive thickening, respectively),
presence or absence of crypt abscesses (0, absent and 1,
present) and the presence or absence of goblet cell deple-
tion (0, absent and 1, present). The histological damage
score was calculated as the addition of the scores corre-
sponding to each feature. High macroscopic and histo-
logical damage scores indicate increased damage in the
intestines.
Secretory IgA (sIgA) assay
Levels of sIgA in the intestinal fluid were determined by en-
zyme linked immunosorbent assay (ELISA) as previously
described [23]. Briefly, microtitre plates (NUNC, Thermo
Scientific, Waltham, MA, USA) were coated with goat
anti-mouse UNLB antibody (Southern Biotechnology,
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night at 4°C. Wells were then washed with a saline
0.05% tween solution and blocked with 200 μL of PBS
with 0.05% (w/v) casein for 1 h at room temperature.
The supernatants obtained from the intestinal fluids
after centrifugation at 432 g for 20 min at 4°C and the
diluted standards in PBS-0.25% casein (1:10) were then
added to the plate and incubated for 1 hour at 37°C.
After washing, goat anti-mouse IgA HRP (Southern
Biotechnology, Birmingham, AL, USA) was added and
plates were incubated for 1 h at 37°C. The colour reaction
was developed at room temperature with the addition of
100 μL/well of orthophenylenediamine (OPD) (1 mg/mL)
(Sigma, St. Louis, MO, USA), 0.04% H2O2 substrate in
sodium citrate buffer. The reaction was finally stopped by
the addition of 20 μL/well of 2 N H2SO4. Absorbance
was measured at 492 nm using a Bio-Rad Model 450
Microplate Reader. Results were expressed as concen-
tration (μg/mL), according to the standard curve.Colon tissue preparation and cytokine assays
For cytokine assays, colons were weighed and homoge-
nized in PBS containing 0.05% (v/v) Tween-20, 0.1 mM
phenylmethylsulphonyl fluoride, 0.1 mM benzethonium
chloride, 10 mM EDTA and 20 KIU AprotininA using a
tissue homogenizer (1 mL/0.1 g). Suspensions were cen-
trifuged at 600 g for 10 min at 4°C and the supernatants
collected for cytokine assay. Concentrations of IL-10,
TNF-α, IL-6, IL-17 were measured by ELISA as de-
scribed previously [23]. Briefly, after coating microtitre
plates (NUNC, Thermo Scientific, Waltham, MA, USA)
with purified monoclonal antibodies reactive to mouse
cytokines IL-10, TNF-α, IL-6, IL-17 (BD, New Jersey,
USA), standards and samples were added and incubated
overnight at 4°C. Biotinylated monoclonal antibodies
anti-mouse IL-10, TNF-α, IL-6, IL-17 were added and
incubated for 1 h at room temperature, after which
peroxidase-labelled streptavidin (Sigma, St. Louis, MO,
USA) was added. A colour reaction was developed at
room temperature with 100 μL/well of OPD (1 mg/mL)
and 0.04% H2O2 substrate in sodium citrate buffer. The
reaction was stopped by the addition of 20 μL/well of
2 N H2SO4. Absorbance was measured at 492 nm using
a Bio-Rad Model 450 Microplate Reader. Results were
expressed as concentration of each cytokine (pg/mL), ac-
cording to the respective standard curve.Statistical analysis
Statistical analyses were performed using the GraphPad
Prism 5.0 software (San Diego, CA, USA) and all results
were expressed as mean ± standard deviation (SD).
Significance of differences among groups was assessed
by Student’s t-test or analysis of variance (ANOVA)followed by a Tukey comparison post-hoc test. Means
were considered statistically different when p < 0.05.
Results
Construction of L. lactis MG1363 pValac:il-10
The pValac:il-10 plasmid was previously constructed by
del Carmen and co-workers and used to construct the
invasive L. lactis MG1363 FnBPA + pValac:il-10 strain.
This strain was tested in an experimental IBD mouse
model induced by TNBS and showed to diminish in-
flammation and damage scores [17]. In this work, we
constructed the non-invasive L. lactis MG1363 pValac:il-
10 strain; the construction was confirmed by PCR (data
not shown). This strain was tested together with the in-
vasive strain in the experimental IBD mouse model in-
duced by DSS.
L. lactis strains carrying the pValac:il-10 plasmid show anti-
inflammatory properties in the DSS-induced colitis in mice
DSS is a well-established animal model of mucosal in-
flammation that has been used for over two decades in
the study of IBD pathogenesis and preclinical studies [8]
and when administrated in drinking water induces an
acute inflammation. C57BL/6 mice were used for the
DSS study as these animals are highly susceptible to
DSS-induced colitis and do not naturally recover from
this disease [21].
Similar to the results previously obtained in a TNBS-
induced colitis mouse model, L. lactis MG1363 FnBPA +
pValac:il-10 was also capable of diminishing inflammation
in the DSS-induced colitis mouse model (Figures 1 and 2).
It was also observed that the non-invasive variant, L. lactis
MG1363 pValac:il-10, was also capable of decreasing the
inflammation in this model. Overall, both groups that re-
ceived the L. lactis strains carrying the pValac:il-10 (pValac:
il-10 groups) showed a lower DAI (Figure 1) and therefore
significant decrease of inflammation, when compared to
the DSS control group and the groups receiving L. lactis
MG1363 and L. lactis MG1363 FnBPA+, which presented
more diarrhoea and bleeding, which was almost absent
in animals from the pValac:il-10 groups. The colon
length of each animal was also measured as a marker
of inflammation-caused injury. As expected, there was
a significant shortening of the colon induced by DSS
treatment (6.92 cm), and the administration of L. lactis
MG1363 (6.96 cm) or L. Lactis MG1363 FnBPA +
(6.93 cm) did not improve it. However, the pValac:il-10
groups showed a significant improvement in colon length,
L. lactis MG1363 pValac:il-10 (7.97 cm) and L. lactis
MG1363 FnBPA pValac:il-10 (8.01 cm), when compared to
the other groups induced with DSS, resembling more the
colon lengths of the control group (8.16 cm). Regarding
body weight loss, all groups maintained similar weight dur-
ing the 8 days of experiment (data not shown).
Figure 1 Inflammatory macroscopic score of experimental
colitis. Macroscopic score of mice treated with DSS that received
the different L. lactis strains compared to the DSS group without
any specific administration. Disease activity index (DAI) was
scored for body weight loss, diarrhoea and rectal bleeding. Bars
represent the mean ± SD of 6 mice per group of two independent
experiments. Asterisks represent statistical significance (**p < 0.01
or ***p < 0.0001). All groups are statistically significant to the
control group (***p < 0.0001).
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performed for all groups, and showed that animals from
the pValac:il-10 groups presented a significant decrease
of the damage score when compared to the DSS group
and the mice that received L. lactis MG1363 or L. lactis
MG1363 FnBPA + (Figure 2A).
Histologically, all samples from the colon of healthy
control mice (group without DSS treatment) presented
themselves within normal standards. The architecture
integrity of the colon was maintained, with goblet cells,
thin submucosa without signs of congestion or oedema
and absence of inflammatory infiltrate in the mucosa
and submucosa (Figure 2B). On the other hand, the colitis
control group (DSS group, Figure 2C) presented intense al-
teration in the mucosal architecture of their colons, with
areas of intense ulceration, absence of glands in large parts
of the mucosa and accentuated depletion of goblet
cells. It was also possible to observe crypt abscesses
and the submucosa was marked by an intense oedema
and inflammatory infiltrate constituted principally by
macrophages. Moreover, thickening of the muscle layerwas also observed. No significant differences were observed
when animals received L. lactis MG1363 (Figure 2D) or
L. lactis MG1363 FnBPA+ (Figure 2F) strains, compared to
the DSS treated control. However, groups that received
L. lactis MG1363 pValac:il-10 (Figure 2E) or L. lactis
MG1363 FnBPA+ pValac:il-10 (Figure 2G) presented a
milder pathological picture, with tendency to normality, a
smaller compromised area and a reduction in the intensity
of the lesion. Reduced inflammatory infiltrates without
erosion of the epithelium, light oedema and diminished
depletion of goblet cells, partially preserving the mucosal
architecture, were also observed.
The pValac:il-10 plasmid increases the production of
secretory IgA
Secretory IgA creates a first-line of defence against mu-
cosal compromise that is lost during IBD. Therefore,
sIgA levels from intestinal fluids of mice were also ana-
lysed. It was observed that only mice that received the
L. lactis MG1363 FnBPA + pValac:il-10 strain showed a
significant increase in the concentration of sIgA when
compared to those from the control group, DSS group
and the groups that did not receive the strains carrying
the pValac:il-10 plasmid (Figure 3). Moreover, this strain
also induced an increased sIgA production when com-
pared to the non-invasive L. lactis MG1363 pValac:il-10
strain.
The administration of L. lactis carrying the pValac:il-10
plasmid modulates the production of cytokines in the
intestinal tissues
Administration of DSS to mice leads to a macrophage-
induced inflammation and tissue damage accompanied
by a cellular cytotoxic-mediated inflammatory response
(macrophage/Th1/Th17 chemotactic profile) during the
progression of colitis [24]. In this regard, in order to de-
termine if the pValac:il-10 plasmid could modulate the
cytokine level in diseased animal, IL-10, TNF-α, IL-6, IL-
17 were measured from colonic tissues. Mice from the
L. lactis MG1363 pValac:il-10 group showed significantly
higher IL-10 levels compared with the control group,
while animals from the L. lactis MG1363 FnBPA + pVa-
lac:il-10 group showed higher IL-10 levels than the
animals from the control and DSS groups (Figure 4A). Re-
garding pro-inflammatory cytokines, TNF-α (Figure 4B)
and IL-17 (Figure 4D) levels did not show significant differ-
ences between the control and test groups, while IL-6 levels
showed significant differences between some of the test and
control groups (Figure 4C). IL-6 increased significantly
(*p < 0.05) in the DSS group when compared to the
control group, and no significant differences with the
groups that received L. lactis MG1363 or L. lactis
MG1363 FnBPA +were observed. The levels of IL-6 were
significantly lower (**p < 0.001) in the pValac:il-10 groups
Figure 2 (See legend on next page.)
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Figure 2 Inflammatory microscopic score of experimental colitis and histopathology of intestinal changes between all groups.
Macroscopic score of mice treated with DSS that received the different L. lactis strains compared to the DSS group without any specific
administration (A). Histological activity index (HAI) was obtained from the colonic tissues stained by H&E. Bars represent the mean ± SD of
6 mice per group of two independent experiments. Asterisks represent statistical significance (**p < 0.01 or ***p < 0.0001). All groups are
statistically significant to the control group (***p < 0.0001). Representative photos obtained from the proximal colon of a mouse from control
group: Control group (B), DSS group (C), and the groups of mice treated with DSS that received L. lactis MG1363 (D) L. lactis MG1363 pValac:il-10 (E)
Proximal colon of diseased mice that received the L. lactis MG1363 FnBPA + (F) or L. lactis MG1363 FnBPA + pValac:il-10 (G). The bar on each image
represents 100 μm. The short white arrows show the depletion of goblet cells; the long white arrow, intense oedema in the submucosa; the short black
arrow, crypt abscesses; and the long black arrow, inflammatory infiltrate (especially of macrophages).
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Discussion
Interleukin 10’s interest in the attempt of developing an ef-
ficient therapy against IBD has grown since it was observed
that IL-10 knockout (IL-10−/−) mice develop spontaneous
enterocolitis when not maintained in germ-free conditions
[25]. Although many advances have been made there still
does not exist any treatment for IBD, showing that the
major drawback to use IL-10 is its correct administration
and directioning to the sites of inflammation.
In order to overcome these problems, new strategies
based on local delivery of IL-10 to the intestinal mucosa
have been developed; high IL-10 concentration at theseFigure 3 Influence of DSS and different bacterial administrations
on gut secretory IgA. Intestinal fluid was collected and total sIgA was
measured by ELISA of wild-type mice, DSS wild-type mice and diseased
mice that received the L. lactis MG1363 strain, L. lactis MG1363
pValac:il-10 strain, L. lactis MG1363 FnBPA + strain or L. lactis
MG1363 FnBPA + pValac:il-10 strain during treatment. Bars represent
the mean N = 6 ± SD of two independent experiments. Asterisks
represent statistical significance *p < 0.05 or **p < 0.001).sites would outweigh the need for high doses and as
such avoid the increase of pro-inflammatory cytokine
production and other undesired side effects.
One such strategy consists in the use of polymer-based
microparticles. These particles encapsulate gelatine nano-
particles containing plasmid DNA expressing murine IL-10
and are capable of releasing these nanoparticles directly at
the desired site of action. These IL-10 gene containing
particles have shown to successfully reduce the levels of in-
flammatory cytokines as well as disease activity scores in
the TNBS-induced model of colitis [26]. However, despite
promising, scale-up to an industrial level appears to be very
expensive and complicated.
Another strategy by Yao and collaborators consists in
a Bifidobacterium longum strain capable of secreting hu-
man IL-10 which was capable of alleviating inflamma-
tory damage of colonic tissue in a DSS-induced mouse
model by blocking the colitis-activated NF-κB pathways
and upregulating CD4 + CD25 + Foxp3+ Treg in blood
and mesenteric lymph nodes [27].
As such, in order to improve IL-10 delivery to the sites
of inflammation using L. lactis, a L. lactis strain express-
ing FnBPA [15,28], that has the capacity to efficiently
internalize and trigger recombinant DNA expression by
human epithelial cells, was used to deliver a eukaryotic
expression vector coding for IL-10 of Mus musculus, pVa-
lac:il-10, directly to host cells in the GIT for recombinant in
situ IL-10 production. This new strategy recently showed
to be capable of diminishing inflammation in a TNBS-
induced mouse model [17].
Following these results and in order to evaluate the
therapeutic effect of the pValac:il-10 plasmid in a larger
context, in the present work we explored the potential
of this therapeutic plasmid in a DSS-induced mouse
model delivered by two L. Lactis strains as a new thera-
peutic strategy for the prevention of intestinal inflamma-
tion. L. lactis MG1363 FnBPA + expresses FnBPA, which
confers the strain the capacity to mediate adhesion to
host tissue and bacterial uptake by eukaryotic cells. To
evaluate if this characteristic results in improved anti-
inflammatory effect, it was compared with the non-invasive
L. lactis MG1363 strain. Our results showed that both
strains were capable of delivering the eukaryotic expression
vector to host cells directly at the sites of inflammation
Figure 4 (See legend on next page.)
Zurita-Turk et al. BMC Biotechnology 2014, 14:73 Page 8 of 11
http://www.biomedcentral.com/1472-6750/14/73
(See figure on previous page.)
Figure 4 The pValac:IL-10 plasmid modulates the production of cytokines in intestinal tissues. IL-10 (A) TNF-α (B), IL-6 (C) and IL-17 (D)
levels in the intestinal tissues of mice from control group (CT), DSS group and mice that received the L. lactis MG1363, L. lactis MG1363 pValac:il-10, L. lactis
MG1363 FnBPA+ or L. lactis MG1363 FnBPA + pValac:il-10. Bars represent the mean ± SD of 6 mice per group of two independent experiments. Asterisks
represent statistical significance (*p< 0.05 or **p< 0.001).
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undesired side-effects, and diminishing the severity of
inflammation by maintaining an anti-inflammatory envir-
onment in the gut.
DSS has the intrinsic capacity to disrupt the epithelial
cell barrier, causing normal gut substances to activate
mucosal macrophages, which in turn produce immuno-
modulatory cytokines. It is generally accepted that DSS
is directly toxic to gut epithelial cells of the basal crypts
and affects the integrity of the mucosal barrier [29]. The
DSS concentration used in the present model triggered
an acute colonic inflammation accompanied by diar-
rhoea and rectal bleeding and did not lead to mortality.
The administration of strains carrying the pValac:il-10
plasmid statistically lowered the macroscopic score com-
pared to the DSS group, regarding diarrhoea and rectal
bleeding. No weight loss was observed within the differ-
ent groups, but this has already been reported earlier
[30]. At histological level, administration of strains carrying
the pValac:il-10 plasmid were capable of decreasing the se-
verity of inflammation, with tendency to normality, demon-
strating the anti-inflammatory effects of this strategy.
IgA is the most abundant immunoglobulin produced,
in its secretory form, at mucosal sites. In the luminal
mucous layer, sIgA protects the intestinal epithelium
against colonization and invasion by pathogens or com-
mensals [31] and therefore helps modulating and con-
trolling inflammation. In our model, no significant
decrease of sIgA was associated with the inflammation
observed in mice treated with DSS that did not receive
the pValac:il-10. The administration of bacteria carrying
the pValac:il-10 plasmid was accompanied by signifi-
cantly increased levels of sIgA only in the intestinal fluid
of mice that received the L. Lactis MG1363 FnBPA +
pValac:il-10 strain, compared to the DSS treated mice.
Moreover, this strain also induced an increased sIgA
production when compared to the L. lactis MG1363
pValac:il-10 strain. We believe that the difference of IgA
production induced by these two strains is due to the differ-
ent cellular entry mechanism these bacteria use after oral
administration. In this regard, L. lactis MG1363 FnBPA +
pValac:il-10 strain induced increased IgA production be-
cause these bacteria invade enterocytes in the epithelium,
while L. lactis MG1363 pValac:il-10 are captured by macro-
phages (as these bacteria have no invasion capacity), which
does not directly lead to the induction of IgA. These results
showed that the L. Lactis MG1363 FnBPA + pValac:il-10
strain could not only have an anti-inflammatory effect inthis model, but also promote the gut immunological barrier
by limiting the penetration of bacteria into host tissues and
therefore protect mice by helping to modulate inflam-
mation. The expression of FnBPA by this strain might
allow for a higher binding capacity and internalization
by eukaryotic cells, thus enhancing the production of
IL-10 and its anti-inflammatory properties.
Cytokines produced in the gut mucosa greatly influ-
ence the resulting immunological outcome; production
of anti-inflammatory cytokines induces mucosal toler-
ance, while high levels of pro-inflammatory cytokines in-
duce inflammation. Since cytokines are major mediators
of inflammation and regulatory activity in the gut mu-
cosa, we analysed the ability of L. lactis strains carrying
the pValac:il-10 plasmid to modulate the production of
cytokines in the colonic tissues of mice. Mice that re-
ceived the pValac:il-10 plasmid, whether delivered by
L. lactis MG1363 or L. lactis MG1363 FnBPA + (pVa-
lac:il-10 groups), showed significantly higher IL-10
levels than the control group (healthy mice), probably
due to a constant and higher production of IL-10 by
the eukaryotic cells of these animals. It is also important to
note that the expression of FnBPA by the bacterial strain
carrying the pValac:il-10 plasmid was associated to signifi-
cantly higher IL-10 levels in the intestinal tissues compared
to the DSS group, where this cytokine was produced as
normal immune response against inflammation. However,
these levels of IL-10 were not significantly different from
those obtained in the L. lactis MG1363 pValac:il-10 group,
nor were associated with significant differences in the levels
of the other cytokines tested in both pValac:il-10 groups.
The lack of significant difference between both strains
carrying the pValac:il-10 plasmid could be explained
by the fact that both cellular entry mechanisms used
by these bacteria (enterocytes invasion by the invasive
strain and capture by macrophages by the non-invasive
strains) lead to efficient and similar IL-10 production;
however, by different cell types.
Pro-inflammatory cytokines, including TNF-α, IL-6
and IL-17, can be produced by T and B lymphocytes,
macrophages and/or neutrophils, which are massively
infiltrated in inflammatory lesions in mice with DSS-
induced acute colitis. This DSS colitis switches from a
Th1-Th17-mediated acute inflammation with increased
levels of TNF-α, IL-6 and IL-17, to a predominant Th2-
mediated inflammatory response that shows a decrease
in TNF-α, IL-6 and IL-17 while increasing levels of anti-
inflammatory cytokines IL-4 and IL-10 [24]. In our
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results only showed higher IL-6 levels in the DSS group
and in the group of mice treated with DSS that received
the L. lactis MG1363 strain, when compared to the con-
trol group (healthy mice). Significant decrease of this
cytokine was observed in the intestinal tissues from mice
that received the pValac:il-10 plasmid, compared to the
DSS group. These results were associated to the increased
IL-10 levels obtained in those animals and confirm the
anti-inflammatory capacity of both strains carrying the
pValac:il-10 plasmid at modulating the gut immune
response.
Conclusions
The results obtained in the present work confirm and
strengthen our previous results that L. lactis MG1363
FnBPA + pValac:il-10 shows to be a good candidate to
maintain an anti-inflammatory status in the GIT and
diminishing intestinal inflammation. Moreover, we here
also showed that not only delivery of the pValac:il-10 plas-
mid by the invasive strain L. lactis MG1363 FnBPA+, but
also by the non-invasive L. lactis MG1363 strain, was ef-
fective at diminishing intestinal inflammation, showing
that this strategy presents potential for therapeutic inter-
vention of IBD. FnBPA expression was not related to more
anti-inflammatory capacity; however, it was associated
with significantly higher IL-10 levels in the intestinal tis-
sues when compared to animals from the DSS group.
Moreover, the highest levels of sIgA in the intestinal fluid
where observed in the animals from the L. lactis MG1363
FnBPA+ pValac:il-10 group, showing better immunomodu-
latory effect by the invasive strain.
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